A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Subcutaneous VIS171 in Participants With Autoimmune Disease(s)
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs VIS 171 (Primary)
- Indications Alopecia; Focal segmental glomerulosclerosis; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 05 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 Feb 2025.
- 03 Feb 2025 New trial record